The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multiple myeloma, inflammatory diseases, and various forms of cancer.
Looking for leads, investment insights, or competitive intelligence?
News about Celgene
Celgene boosted the price of a 10-milligram dose of Revlimid by 3.5% to $719.82 effective Jan. 3.
Must-read business news, delivered every morning.
It's one of the largest pharmaceutical-company mergers ever.
The economy and the stock market don’t always march in lockstep, and investors got a sharp reminder of that fact this fall. Parade-and-fireworks-worthy GDP growth and employment numbers shared the spotlight with an ugly market slide that took some previously beloved stocks into bear-market territory. Fears about inflation and trade tensions were among the culprits; […]
Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.